HRP20161444T1 - Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo - Google Patents
Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo Download PDFInfo
- Publication number
- HRP20161444T1 HRP20161444T1 HRP20161444TT HRP20161444T HRP20161444T1 HR P20161444 T1 HRP20161444 T1 HR P20161444T1 HR P20161444T T HRP20161444T T HR P20161444TT HR P20161444 T HRP20161444 T HR P20161444T HR P20161444 T1 HRP20161444 T1 HR P20161444T1
- Authority
- HR
- Croatia
- Prior art keywords
- minutes
- sustained
- use according
- preparation
- pharmaceutically active
- Prior art date
Links
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 title claims 3
- 229960003150 bupivacaine Drugs 0.000 title claims 3
- 230000003444 anaesthetic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 8
- 239000003405 delayed action preparation Substances 0.000 claims 7
- 238000002360 preparation method Methods 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003589 local anesthetic agent Substances 0.000 claims 6
- 239000007937 lozenge Substances 0.000 claims 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 238000005192 partition Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- -1 amide compound Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 229940037530 cough and cold preparations Drugs 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 229960003976 etidocaine Drugs 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229940091249 fluoride supplement Drugs 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 229960004288 levobupivacaine Drugs 0.000 claims 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims 1
- 235000011475 lollipops Nutrition 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 229960001549 ropivacaine Drugs 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 235000021091 sugar-based sweeteners Nutrition 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (13)
1. Pripravak s produljenim oslobađanjem koji sadrži kao lokalni anestetik amidni spoj koji ima vrijednost koeficijenta raspodjele oktanol/voda od barem 100, ili njegovu sol, formuliran za lokalnu primjenu u usta ili grlo subjekta u obliku pastile za uporabu za liječenje oralnog mukozitisa kod subjekta koji je podvrgnut liječenju raka.
2. Pripravak s produljenim oslobađanjem prema zahtjevu 1 naznačen time da spoj ima vrijednost koeficijenta raspodjele oktanol/voda od barem 300.
3. Pripravak s produljenim oslobađanjem prema zahtjevu 1 naznačen time da spoj je bupivakain, ropivakain, etidokain ili levobupivakain ili farmaceutski aktivna sol bilo kojeg od tih spojeva, kao što je hidroklorid.
4. Pripravak s produljenim oslobađanjem za uporabu prema zahtjevu 1, naznačen time da spoj je bupivakain ili farmaceutski aktivna sol navedenog spoja, kao što je hidroklorid.
5. Pripravak s produljenim oslobađanjem za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da je lokalni anestetik ili njegova farmaceutski aktivna sol prisutan u količini od 0.1 do 75 mg, poželjno 0.1 do 50 mg, na primjer 5 mg, 10 mg, 25 mg ili 50 mg, po oralnom obliku doziranja.
6. Pripravak s produljenim oslobađanjem za uporabu prema bilo kojem od prethodnih zahtjeva naznačen time da je formuliran da osigura produljeno oslobađanje lokalnog anestetika ili njegove farmaceutski aktivne soli kroz vremenski period od barem 20 minuta, na primjer barem 60 minuta, na primjer od oko 70 minuta, kao što je do oko 80 minuta, na primjer do oko 90 minuta, kao što je do oko 100 minuta, na primjer do oko 2 sata, kao što je do oko 3 sata, na primjer do oko 4 sata, kao što je do oko 5 sati, na primjer do oko 6 sati.
7. Pripravak s produljenim oslobađanjem za uporabu prema bilo kojem od prethodnih zahtjeva naznačen time da je vršna koncentracija u krvi kod čovjeka, poslije oralne primjene pripravka na čovjeka i zadržavanja pripravka u usnoj šupljini čovjeka sve do potpunog otapanja pripravka, u prosjeku od 15 do 45 minuta, poželjno 25 do 35 minuta, poželjnije oko 30 minuta, poslije navedenog otapanja.
8. Pripravak s produljenim oslobađanjem za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da je pripravak u obliku koji je odabran iz skupine koju čine praškaste pastile, sirupaste pastile i granulirane pastile, pastile sa aplikatorom/lizalice.
9. Pripravak s produljenim oslobađanjem za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da lokalni anestetik ili njegova farmaceutski aktivna sol je jedini aktivni sastojak.
10. Pripravak s produljenim oslobađanjem za uporabu prema bilo kojem od zahtjeva 1 do 9, naznačen time da dodatno sadrži drugi aktivni sastojak koji je odabran iz skupine koju čine antimikrobna sredstva kao što su antivirusna sredstva, antimikotička sredstva i antibiotici; protuupalna sredstva, biološka sredstva, kemoterapijska/protutumorska sredstva, pripravci za kašalj i prehladu uključujući ali nije ograničeno na sredstva protiv kašlja, ekspektoranse, dekongestive, spojeve koji otpuštaju fluorid i druge proizvode za zubnu higijenu, sredstva za stimulaciju stvaranja sline, druga anestetička sredstva i antiemetike.
11. Pripravak s produljenim oslobađanjem za uporabu prema bilo kojem od zahtjeva naznačen time da sadrži
0.1- 5% (w/w) lokalnog anestetika ili njegovu farmaceutski aktivnu sol,
70 - 85 % (w/w) punila ili vezivnog sredstva,
0 -10% (w/w) sredstva za poboljšanje klizivosti ili lubrikanta,
0.5 - 5 % (w/w) zaslađivača koji nije na bazi šećera i
5 - 20 % (w/w) arome.
12. Pripravak s produljenim oslobađanjem za uporabu prema bilo kojem od zahtjeva 1 do 10 naznačen time da sadrži
0.01- 5 % (w/w) lokalnog anestetika ili njegovu farmaceutski aktivnu sol,
70 - 95 % (w/w) baze,
3 - 20 % (w/w) arome.
13. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da tretman dovodi do smanjenja ozbiljnosti simptoma koji odgovaraju smanjenju vrijednosti kada je mjerena u skladu s VAS vrijenosti od barem 15% unutar 10 minuta od početka tretmana i/ili barem 20% poslije 30 minuta tretmana i/ili barem 30% 1 sat nakon početka tretmana.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170213 | 2011-04-29 | ||
| DKPA201170225 | 2011-05-06 | ||
| EP12719345.6A EP2701681B1 (en) | 2011-04-29 | 2012-04-27 | Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat |
| PCT/EP2012/057864 WO2012146763A1 (en) | 2011-04-29 | 2012-04-27 | Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161444T1 true HRP20161444T1 (hr) | 2016-12-16 |
Family
ID=59078879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161444TT HRP20161444T1 (hr) | 2011-04-29 | 2016-11-02 | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo |
| HRP20210487TT HRP20210487T1 (hr) | 2011-04-29 | 2021-03-25 | Farmaceutski sastavi koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210487TT HRP20210487T1 (hr) | 2011-04-29 | 2021-03-25 | Farmaceutski sastavi koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956211B2 (hr) |
| EP (3) | EP2701681B1 (hr) |
| CA (2) | CA2972211C (hr) |
| CY (2) | CY1118474T1 (hr) |
| DK (2) | DK3284459T3 (hr) |
| ES (2) | ES2857252T3 (hr) |
| HR (2) | HRP20161444T1 (hr) |
| HU (2) | HUE030921T2 (hr) |
| LT (2) | LT3284459T (hr) |
| PL (2) | PL3284459T3 (hr) |
| PT (2) | PT3284459T (hr) |
| RS (2) | RS61753B1 (hr) |
| SI (2) | SI3284459T1 (hr) |
| SM (1) | SMT201700010B (hr) |
| WO (1) | WO2012146763A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2857252T3 (es) * | 2011-04-29 | 2021-09-28 | Moberg Pharma Ab | Composiciones farmacéuticas que comprenden un anestésico local tal como bupivacaína para administración local en la boca o la garganta |
| PL2849724T3 (pl) * | 2012-05-16 | 2019-01-31 | Orexa B.V. | Środki do ułatwiania przyjmowania i utrzymywania spożytego pokarmu |
| ES2905771T3 (es) * | 2015-01-06 | 2022-04-12 | Cellix Bio Private Ltd | Composiciones y procedimientos para el tratamiento de la inflamación y del dolor |
| CN104758592A (zh) * | 2015-04-11 | 2015-07-08 | 河南金鸿堂制药有限公司 | 一种治疗风火牙痛的中药胶囊制剂 |
| US10555952B2 (en) | 2015-06-19 | 2020-02-11 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
| US20200297734A1 (en) | 2015-06-19 | 2020-09-24 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
| RU2604576C1 (ru) * | 2015-12-01 | 2016-12-10 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения |
| US11571492B2 (en) | 2017-08-04 | 2023-02-07 | Hcs Innovation, Llc | Natural polymer-based tissue adhesive with healing-promoting properties |
| US12102729B2 (en) | 2017-08-04 | 2024-10-01 | Hcs Innovation, Llc | Natural polymer-based tissue adhesive with healing-promoting properties |
| US10835635B2 (en) | 2017-08-04 | 2020-11-17 | Hcs Innovation, Llc | Natural polymer based tissue adhesive with healing promoting properties |
| WO2019231858A1 (en) * | 2018-06-01 | 2019-12-05 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
| CN115515581A (zh) | 2020-01-10 | 2022-12-23 | 帕西拉制药股份有限公司 | 通过给予缓释脂质体麻醉组合物治疗疼痛 |
| US20230080593A1 (en) | 2020-01-10 | 2023-03-16 | Pacira Pharmaceuticals, Inc. | Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions |
| AU2021381054A1 (en) * | 2020-11-21 | 2023-05-25 | Cellix Bio Private Limited | Pharmaceutical compositions for use in the management and treatment of pain |
| CN116997338A (zh) | 2021-01-11 | 2023-11-03 | 帕西拉制药股份有限公司 | 用缓释脂质体麻醉剂组合物治疗髋部疼痛 |
| EP4308084A2 (en) * | 2021-03-19 | 2024-01-24 | Pacira Pharmaceuticals, Inc. | Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions |
| WO2023187664A1 (en) * | 2022-03-30 | 2023-10-05 | Avaca Pharma Private Limited | A pharmaceutical composition for the treatment of immune system mediated diseases |
| WO2024064898A2 (en) * | 2022-09-22 | 2024-03-28 | Rythera Therapeutics Inc. | Composition and method for prevention and treatment of cutaneous radiation injury |
| US11918565B1 (en) | 2022-11-03 | 2024-03-05 | Pacira Pharmaceuticals, Inc. | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3511914A (en) | 1967-01-31 | 1970-05-12 | Schering Corp | Throat lozenge vehicle |
| GB2133284A (en) | 1983-01-07 | 1984-07-25 | English Grains Limited | Resilient pharmaceutical unit for treating mouth ulcers |
| US4853212A (en) | 1987-07-13 | 1989-08-01 | Warner-Lambert Company | Reduced base content chewing gum compositions having anesthetic properties |
| US4822597A (en) * | 1987-07-13 | 1989-04-18 | Warner-Lambert Company | Anesthetic-containing chewing gum compositions |
| GB8810951D0 (en) | 1988-05-09 | 1988-06-15 | Innovata Biomed Ltd | Buccal local anaesthetic |
| GB8928196D0 (en) | 1989-12-13 | 1990-02-14 | Merrell Dow Pharmaceuticals Li | Pharmaceutical lozenges |
| US6221840B1 (en) | 1991-02-14 | 2001-04-24 | The General Hospital Corporation | Intestinal trefoil proteins |
| US5332576A (en) | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| WO1994008550A1 (en) | 1992-10-09 | 1994-04-28 | The Procter & Gamble Company | Anaesthetic compositions |
| US5399354A (en) | 1993-05-28 | 1995-03-21 | Mcneil-Ppc, Inc. | Process for making a hard-candy based oral pharmaceutical lozenge containing an antacid |
| US20030186884A1 (en) | 2000-06-08 | 2003-10-02 | Markland Francis S. | Contortrostatin (CN) and methods for its use in preventing metastasis and other conditions |
| US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
| US5713852A (en) | 1995-06-07 | 1998-02-03 | Alza Corporation | Oral dosage and method for treating painful conditions of the oral cavity |
| WO1996041616A1 (en) | 1995-06-09 | 1996-12-27 | Euro-Celtique, S.A. | Formulations and methods for providing prolonged local anesthesia |
| US5614207A (en) | 1995-06-30 | 1997-03-25 | Mcneil-Ppc, Inc. | Dry mouth lozenge |
| US5912007A (en) | 1996-02-29 | 1999-06-15 | Warner-Lambert Company | Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same |
| US6183775B1 (en) | 1996-05-13 | 2001-02-06 | Novartis Consumer Health S.A. | Buccal delivery system |
| JPH11511763A (ja) | 1996-06-24 | 1999-10-12 | ユーロ―セルティーク，エス．エイ． | 安全な局所麻酔の提供方法 |
| WO1997049384A1 (en) | 1996-06-26 | 1997-12-31 | Board Of Regents, The University Of Texas System | Hot-melt extrudable pharmaceutical formulation |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9710521D0 (en) | 1997-05-22 | 1997-07-16 | Boots Co Plc | Process |
| US8765177B2 (en) | 1997-09-12 | 2014-07-01 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6103257A (en) * | 1998-07-17 | 2000-08-15 | Num-Pop, Inc. | System for delivering pharmaceuticals to the buccal mucosa |
| US7163705B2 (en) | 1998-12-15 | 2007-01-16 | Wm. Wrigley Jr. Company | Coated chewing gum product and method of making |
| US6773716B2 (en) | 1999-04-06 | 2004-08-10 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
| US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
| US6946118B1 (en) | 1999-09-14 | 2005-09-20 | Orapharma, Inc. | Formulations for treating or preventing mucositis |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| CA2407683C (en) | 2000-04-28 | 2010-04-13 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
| WO2001089476A1 (en) | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| EP1559418A1 (en) | 2000-06-26 | 2005-08-03 | EpiCept Corporation | Compositions for treating pain of the mucous membrane |
| US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| BRPI0115531B1 (pt) | 2000-11-22 | 2015-10-13 | Rxkinetix Inc | composição terapêutica útil para o tratamento de mucosite em um local de mucosa como efeito colateral de terapia de câncer |
| EP1236466B1 (en) * | 2001-02-28 | 2011-09-21 | Axiomedic Ltd. | Solid self-adhesive compositions for topical treatment of oral mucosal disorders |
| WO2002087544A1 (en) | 2001-04-17 | 2002-11-07 | Wm. Wrigley Jr. Company | Flavored product containing medicament or other active agent |
| US7820688B2 (en) | 2001-04-27 | 2010-10-26 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
| US20040254128A1 (en) | 2001-08-10 | 2004-12-16 | Seiichi Kobayashi | Treatment and prevention of heat shock protein-associated diseases and conditions |
| US7470545B2 (en) | 2001-11-05 | 2008-12-30 | Rohm And Haas Company | Buccal dissolution of active substances |
| US20030114534A1 (en) | 2001-12-17 | 2003-06-19 | Peter Arsenault | Pharmaceutical preparation for apthous ulcers |
| US20030175360A1 (en) * | 2002-02-22 | 2003-09-18 | Renzo Luzzatti | Symptomatic relief of gastrointestinal disorders |
| US7074426B2 (en) | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
| US6919348B2 (en) | 2002-05-02 | 2005-07-19 | Edward T. Wei | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
| CA2501614A1 (en) | 2002-10-07 | 2004-04-22 | Orapharma, Inc. | Mucoadhesive tetracycline formulations |
| AU2003299568B2 (en) | 2002-11-27 | 2010-07-22 | Ampio Pharmaceuticals, Inc. | Treatment of diseases and conditions mediated by increased phosphorylation |
| SE0302947D0 (sv) | 2003-01-24 | 2003-11-07 | Magle Ab | A composition material for transmucosal delivery |
| US20040151771A1 (en) * | 2003-02-04 | 2004-08-05 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
| US8992974B2 (en) | 2003-02-24 | 2015-03-31 | Pharmaceuticals Productions, Inc. | Transmucosal drug delivery system |
| MXPA05011724A (es) | 2003-05-02 | 2006-01-23 | Warner Lambert Co | Productos dulces para liberar agentes farmaceuticamente activos a la garganta. |
| US7713440B2 (en) | 2003-10-08 | 2010-05-11 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
| US20050152972A1 (en) * | 2004-01-14 | 2005-07-14 | Mohinder Singh | Soft chewable anesthetic lozenges |
| US7452523B2 (en) | 2004-01-27 | 2008-11-18 | Gilead Sciences, Inc. | Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks |
| JP4252497B2 (ja) | 2004-06-07 | 2009-04-08 | 日東電工株式会社 | 上部消化管内視鏡検査前処置用局所麻酔製剤 |
| DE202004016078U1 (de) | 2004-09-22 | 2005-11-10 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Schleimdrogenbasierte Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums |
| DE202004016077U1 (de) | 2004-09-22 | 2005-11-10 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums |
| DE102004052308B4 (de) | 2004-10-12 | 2013-04-04 | Divapharma-Knufinke Arzneimittelwerk Gmbh | Octenidinhaltige Lutschtabletten gegen entzündliche Erkrankungen des Mund- und Rachenraums |
| IL166114A0 (en) | 2005-01-03 | 2006-01-15 | Calcident Active Ltd | Long-acting controlled-release pharmaceutical preparation for use in the oral cavity |
| PL1848403T3 (pl) | 2005-01-14 | 2010-09-30 | Camurus Ab | Preparaty bioadhezyjne o działaniu miejscowym |
| US20060263306A1 (en) | 2005-05-19 | 2006-11-23 | Pauline Pan | Compositions having improved substantivity |
| US20060280695A1 (en) | 2005-06-08 | 2006-12-14 | Giles Brian C | Methods and compositions for the prevention, suppression and elimination of oral pain |
| US20070042027A1 (en) | 2005-08-22 | 2007-02-22 | Haley Jeffrey T | Water soluble anesthetic in an oral patch of hydrophilic gums |
| WO2007025142A2 (en) | 2005-08-26 | 2007-03-01 | Ladd Byron S | Gel compositions comprising a combination of an antiseptic and an anesthetic agent for treating surface areas in medical and surgical procedures |
| WO2007089652A2 (en) | 2006-01-27 | 2007-08-09 | Cadbury Adams Usa Llc | Flavor-enhancing compositions, methods of manufacture, and methods of use |
| WO2009043134A1 (en) | 2007-10-03 | 2009-04-09 | Myrex Pharmaceuticals Inc. | Mouthwash and method of using same for the treatment of mucositis or stomatitis |
| EP2015761A4 (en) | 2006-03-29 | 2009-07-29 | Naveh Pharma 1996 Ltd | METHODS AND COMPOSITION FOR THE TREATMENT OF THROAT SORE |
| US20100247453A1 (en) * | 2006-07-12 | 2010-09-30 | Thomas L. Jones | Composition and method of treating a sore throat |
| WO2008060764A2 (en) | 2006-10-05 | 2008-05-22 | Drugtech Corporation | Topical therapies for oral mucositis and other conditions |
| PL2056675T3 (pl) | 2006-10-12 | 2019-08-30 | Galera Labs, Llc | Metody leczenia zapalenia błony śluzowej jamy ustnej |
| DE502006006810D1 (de) | 2006-11-06 | 2010-06-02 | Lohmann & Rauscher Gmbh & Co | Produkt zur Versorgung von Entzündungen, Druckstellen und/oder Aphten im Oralbereich sowie Verwendung eines solchen Produkts |
| US20080146672A1 (en) | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
| US20090081294A1 (en) | 2007-09-26 | 2009-03-26 | Gin Jerry B | Sustained release dosage form for lubricating an oral cavity |
| US20090081291A1 (en) | 2007-09-26 | 2009-03-26 | Gin Jerry B | Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User |
| GB0722349D0 (en) | 2007-11-15 | 2007-12-27 | Reckitt Benckiser Healthcare | Use of anti-bacterial compounds having an anaesthetic effect |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| DE102008034748A1 (de) | 2008-07-24 | 2010-01-28 | Tesa Se | Flexibles beheiztes Flächenelement |
| DE202009000862U1 (de) | 2009-01-07 | 2009-04-16 | Klosterfrau Berlin Gmbh | Dosiereinheit und Zusammensetzung zur Behandlung von entzündlichen Erkrankungen des Mund- und Rachenraums |
| US20100297265A1 (en) | 2009-05-20 | 2010-11-25 | Mckinney Jeffrey A | Optimal compositions and methods for treating oral disease and pain |
| ES2857252T3 (es) * | 2011-04-29 | 2021-09-28 | Moberg Pharma Ab | Composiciones farmacéuticas que comprenden un anestésico local tal como bupivacaína para administración local en la boca o la garganta |
-
2012
- 2012-04-27 ES ES17189690T patent/ES2857252T3/es active Active
- 2012-04-27 US US14/114,669 patent/US9956211B2/en active Active
- 2012-04-27 RS RS20210366A patent/RS61753B1/sr unknown
- 2012-04-27 RS RS20161017A patent/RS55372B1/sr unknown
- 2012-04-27 SI SI201231905T patent/SI3284459T1/sl unknown
- 2012-04-27 SI SI201230797A patent/SI2701681T1/sl unknown
- 2012-04-27 CA CA2972211A patent/CA2972211C/en active Active
- 2012-04-27 DK DK17189690.5T patent/DK3284459T3/da active
- 2012-04-27 EP EP12719345.6A patent/EP2701681B1/en active Active
- 2012-04-27 WO PCT/EP2012/057864 patent/WO2012146763A1/en active Application Filing
- 2012-04-27 PL PL17189690T patent/PL3284459T3/pl unknown
- 2012-04-27 EP EP16192891.6A patent/EP3173069A1/en not_active Withdrawn
- 2012-04-27 EP EP17189690.5A patent/EP3284459B1/en active Active
- 2012-04-27 PT PT171896905T patent/PT3284459T/pt unknown
- 2012-04-27 HU HUE12719345A patent/HUE030921T2/en unknown
- 2012-04-27 CA CA2860373A patent/CA2860373C/en active Active
- 2012-04-27 DK DK12719345.6T patent/DK2701681T3/en active
- 2012-04-27 PL PL12719345T patent/PL2701681T3/pl unknown
- 2012-04-27 ES ES12719345.6T patent/ES2605814T3/es active Active
- 2012-04-27 PT PT127193456T patent/PT2701681T/pt unknown
- 2012-04-27 LT LTEP17189690.5T patent/LT3284459T/lt unknown
- 2012-04-27 HU HUE17189690A patent/HUE053776T2/hu unknown
- 2012-04-27 LT LTEP12719345.6T patent/LT2701681T/lt unknown
-
2016
- 2016-11-02 HR HRP20161444TT patent/HRP20161444T1/hr unknown
-
2017
- 2017-01-10 SM SM201700010T patent/SMT201700010B/it unknown
- 2017-01-18 CY CY20171100068T patent/CY1118474T1/el unknown
-
2018
- 2018-04-09 US US15/948,718 patent/US10493068B2/en active Active
-
2021
- 2021-03-25 HR HRP20210487TT patent/HRP20210487T1/hr unknown
- 2021-03-30 CY CY20211100275T patent/CY1124219T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1124219T1 (el) | 2022-05-27 |
| CA2860373A1 (en) | 2012-11-01 |
| EP3173069A1 (en) | 2017-05-31 |
| CY1118474T1 (el) | 2017-07-12 |
| WO2012146763A1 (en) | 2012-11-01 |
| EP2701681B1 (en) | 2016-10-19 |
| US20180221358A1 (en) | 2018-08-09 |
| RS55372B1 (sr) | 2017-03-31 |
| LT3284459T (lt) | 2021-04-12 |
| SMT201700010B (it) | 2017-03-08 |
| RS61753B1 (sr) | 2021-05-31 |
| PT3284459T (pt) | 2021-03-30 |
| DK2701681T3 (en) | 2017-01-09 |
| LT2701681T (lt) | 2016-12-12 |
| SI2701681T1 (sl) | 2017-01-31 |
| PL3284459T3 (pl) | 2021-06-28 |
| DK3284459T3 (en) | 2021-03-15 |
| EP3284459B1 (en) | 2021-01-06 |
| ES2605814T3 (es) | 2017-03-16 |
| US10493068B2 (en) | 2019-12-03 |
| EP2701681A1 (en) | 2014-03-05 |
| PT2701681T (pt) | 2016-12-16 |
| US20140296293A1 (en) | 2014-10-02 |
| CA2860373C (en) | 2017-08-15 |
| PL2701681T3 (pl) | 2017-03-31 |
| HUE030921T2 (en) | 2017-06-28 |
| EP3284459A1 (en) | 2018-02-21 |
| CA2972211C (en) | 2019-02-05 |
| SI3284459T1 (sl) | 2021-07-30 |
| HRP20210487T1 (hr) | 2021-05-14 |
| HUE053776T2 (hu) | 2021-07-28 |
| CA2972211A1 (en) | 2012-11-01 |
| ES2857252T3 (es) | 2021-09-28 |
| US9956211B2 (en) | 2018-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161444T1 (hr) | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| AU2009294612B2 (en) | Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers. | |
| JP2006516648A5 (hr) | ||
| JP2009529561A5 (hr) | ||
| JP2013121983A5 (hr) | ||
| HRP20231439T1 (hr) | Oralne formulacije citidinskih analoga i postupci za njihovu uporabu | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| JP2005512995A5 (hr) | ||
| HUP0204163A2 (hu) | Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására | |
| JP2006504795A5 (hr) | ||
| HRP20191854T1 (hr) | Orodisperzibilni dezmopresin za povećanje početnog razdoblja sna neometanog s nokturijom | |
| WO2009106963A2 (en) | Dental composition for preventing and treating stomatitis and mouth ulcers | |
| JP2010522137A5 (hr) | ||
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| RU2014115287A (ru) | Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения | |
| US10646476B2 (en) | Method for treatment of humoral secretion dysfunctions | |
| HRP20171678T1 (hr) | Postupci za smanjenje prejedanja ili kompulzivnog jedenja | |
| TWI547289B (zh) | 發泡性組成物 | |
| CA2495463A1 (en) | Extended release composition containing tramadol | |
| JP2020500864A5 (hr) | ||
| WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
| MX2015002946A (es) | Composiciones farmaceuticas que comprenden flurbiprofeno. | |
| JP2012097034A5 (hr) | ||
| JP2017530142A5 (hr) | ||
| JP2006347958A (ja) | 咽頭粘膜抗炎症スプレー剤 |